

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

NCT07065968

Status	RECRUITING
Phase	Phase 2
Sponsor	Peking University People's Hospital
Enrollment	132 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged ≥18 years;
- Newly diagnosed, treatment naïve ITP patients;
- Patients with a platelet count $<30 \times 10^9/L$ or a platelet count $<50 \times 10^9/L$ with bleeding manifestations at the enrollment;
- Willing and able to sign written informed consent.

Exclusion (10)

- Secondary ITP such as drug-related thrombocytopenia, viral infection (HIV, hepatitis B virus, or hepatitis C virus);
- Pre-existing acute or chronic liver disease, or ALT/AST greater than 2 times the upper limit of normal (ULN);
- Severe cardiac, renal, hepatic, or respiratory insufficiency;
- Severe immunodeficiency;
- Pregnancy or lactation;

... and 5 more (see full listing online)

Locations (3 total)

Peking University First Hospital, Beijing, Beijing Municipality, China

Peking University Institute of Hematology, Peking University People's Hospital, Beijing, Beijing Municipality, China

Peking University Third Hospital, Beijing, Beijing Municipality, China